Endoscopic Submucosal Dissection Versus Esophagectomy for Early Esophageal Carcinoma：a Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Esophageal Cancer
- Sponsor
- Changhai Hospital
- Enrollment
- 191
- Locations
- 1
- Primary Endpoint
- overall survival (OS)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Endoscopic submucosal dissection (ESD) is a minimally invasive alternative to esophagectomy for early esophageal squamous cell carcinoma (EESCC), The data of EESCC patients who received ESD or esophagectomy were retrospectively analyzed,The aim of this study was to compare the efficacy and safety of ESD and esophagectomy in EESCC,Risk factors affecting the prognosis of patients with early esophageal squamous cell carcinoma were analyzed.
Detailed Description
Endoscopic submucosal dissection (ESD) is a minimally invasive alternative to esophagectomy for early esophageal squamous cell carcinoma (EESCC).The aim of this study was to compare the efficacy and safety of ESD and esophagectomy in EESCC，The data of EESCC patients who received ESD or esophagectomy were retrospectively analyzed. Overall survival (OS), disease specific survival (DSS), recurrence free survival (RFS), and procedure-related variables were compared between ESD and esophagectomy patients.Risk factors affecting the prognosis of patients with early esophageal squamous cell carcinoma were analyzed.
Investigators
Zhaoshen Li
Director of Gastroenterology，Changhai Hospital；Academician of Chinese Academy of Engineering
Changhai Hospital
Eligibility Criteria
Inclusion Criteria
- •Mucosal or submucosal squamous cell carcinoma of the esophagus
- •no lymph node involvement or distant metastasis on computed tomography (CT) or pathology;
Exclusion Criteria
- •Tis premalignant lesions (high-grade intraepithelial neoplasia;HGIN)
- •patients with neoadjuvant therapy
- •patients combined with severe diseases of other organs
Outcomes
Primary Outcomes
overall survival (OS)
Time Frame: 10 years
OS was measured from the date of ESD or esophagectomy until death from any cause
Recurrence free survival (RFS)
Time Frame: 10 years
RFS was measured from the date of ESD or esophagectomy until the first recurrence or metastasis
Disease specific survival (DSS)
Time Frame: 10 years
DSS was measured from the date of ESD or esophagectomy until death resulting from ESCC
Secondary Outcomes
- R0 resection(15 days)
- operation time(12 hours)
- adjuvant therapy(10 years)
- postoperative complications(30 days)
- Post-operative hospitalization days(30 days)